Literature DB >> 8957489

Surgical treatment of Graves' disease: subtotal or total thyroidectomy?

P Miccoli1, P Vitti, T Rago, P Iacconi, L Bartalena, F Bogazzi, E Fiore, R Valeriano, L Chiovato, R Rocchi, A Pinchera.   

Abstract

BACKGROUND: The extent of thyroidectomy in Graves' disease is still controversial. We compared the outcome of two groups of patients with Graves' disease who underwent total and subtotal thyroidectomy, respectively.
METHODS: One hundred forty patients were treated by subtotal (ST, n = 80) or total thyroidectomy (TT, n = 60) between 1988 and 1994 for a large goiter or recurrence of hyperthyroidism after antithyroid drugs. Surgical complications, relapse of hyperthyroidism, and serum levels of antibodies were evaluated.
RESULTS: Thyroid-stimulating hormone receptor and thyroperoxidase antibodies significantly decreased in 44 of 60 and in 27 of 60, respectively, of TT patients and in 65 of 80 and 8 of 80, respectively, of ST patients. Thyroid-stimulating hormone antibody levels increased in three ST patients who had relapse of hyperthyroidism and in no TT patients; thyroperoxidase antibodies increased in nine ST patients (four with relapse of hyperthyroidism) and in no TT patients. Vocal cord palsy occurred in two ST (2.5%) and in 1 TT (1.7%) patients; hypoparathyroidism occurred in three ST (3.8%) and in two (3.3%) TT patients.
CONCLUSIONS: Total thyroidectomy does not present more complications with respect to subtotal thyroidectomy, but it avoids the worsening of thyroid humoral autoimmunity and the relapse of hyperthyroidism. Thus it could represent the treatment of choice in Graves' disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8957489     DOI: 10.1016/s0039-6060(96)80049-3

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  29 in total

1.  Alternating from subtotal thyroid resection to total thyroidectomy in the treatment of Graves' disease prevents recurrences but increases the frequency of permanent hypoparathyroidism.

Authors:  Johannes Järhult; Per-Olof Andersson; Linda Duncker
Journal:  Langenbecks Arch Surg       Date:  2011-12-09       Impact factor: 3.445

2.  Analysis of the factors that have an effect on hypocalcemia following thyroidectomy.

Authors:  Doğa Kalyoncu; Doğan Gönüllü; Mehmet Lari Gedik; Muzaffer Er; Erol Kuroğlu; Ayşenur A İğdem; Ferda Nihat Koksoy
Journal:  Ulus Cerrahi Derg       Date:  2013-12-01

Review 3.  Ablative or non-ablative therapy for Graves' hyperthyroidism in patients with ophthalmopathy?

Authors:  C Marcocci; L Bartalena; A Pinchera
Journal:  J Endocrinol Invest       Date:  1998 Jul-Aug       Impact factor: 4.256

4.  Treatment of hyperthyroidism in young people.

Authors:  T D Cheetham; I A Hughes; N D Barnes; E P Wraight
Journal:  Arch Dis Child       Date:  1998-03       Impact factor: 3.791

5.  Incidence and risk factors for injuries to the recurrent laryngeal nerve during neck surgery in the moderate-volume setting.

Authors:  Kalle Landerholm; Anna-Maria Wasner; Johannes Järhult
Journal:  Langenbecks Arch Surg       Date:  2014-01-09       Impact factor: 3.445

6.  Total thyroidectomy in Basedow-Graves' disease treatment: our experience.

Authors:  M Barbuscia; A Querci; A Tonante; D Paparo; F Taranto; A Ilacqua; E Gagliano; A Milone
Journal:  G Chir       Date:  2015 May-Jun

7.  SUBTOTAL THYROIDECTOMY IN THE MANAGEMENT OF GRAVE'S DISEASE.

Authors:  P J Vincent; M K Garg; Y Singh; V P Bhalla; S Datta
Journal:  Med J Armed Forces India       Date:  2011-07-21

Review 8.  Total thyroid ablation in Graves' orbitopathy.

Authors:  F Menconi; M Leo; P Vitti; C Marcocci; M Marinò
Journal:  J Endocrinol Invest       Date:  2015-03-05       Impact factor: 4.256

9.  Video-assisted thyroidectomy for Graves' disease: report of a preliminary experience.

Authors:  P Berti; G Materazzi; D Galleri; G Donatini; M Minuto; P Miccoli
Journal:  Surg Endosc       Date:  2004-06-23       Impact factor: 4.584

10.  Propylthiouracil (PTU) Hepatoxicity in Children and Recommendations for Discontinuation of Use.

Authors:  Scott A Rivkees; Donald R Mattison
Journal:  Int J Pediatr Endocrinol       Date:  2009-04-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.